US6846968B1
(en)
|
1988-02-26 |
2005-01-25 |
Large Scale Biology Corporation |
Production of lysosomal enzymes in plants by transient expression
|
US5179023A
(en)
|
1989-03-24 |
1993-01-12 |
Research Corporation Technologies, Inc. |
Recombinant α-galactosidase a therapy for Fabry disease
|
JPH11507231A
(ja)
|
1995-06-07 |
1999-06-29 |
イェール ユニバーシティ |
アデノ関連ウイルスベクターの経口送達
|
US6458574B1
(en)
|
1996-09-12 |
2002-10-01 |
Transkaryotic Therapies, Inc. |
Treatment of a α-galactosidase a deficiency
|
AU762400B2
(en)
|
1996-09-13 |
2003-06-26 |
Shire Human Genetic Therapies, Inc. |
Therapy for alpha-galactosidase a deficiency
|
US6083725A
(en)
|
1996-09-13 |
2000-07-04 |
Transkaryotic Therapies, Inc. |
Tranfected human cells expressing human α-galactosidase A protein
|
ES2581828T3
(es)
|
1996-09-13 |
2016-09-07 |
Shire Human Genetic Therapies, Inc. |
Proceso de purificación de alfa-galactosidasa A
|
US20020082224A1
(en)
|
1997-01-14 |
2002-06-27 |
Douglas J. Jolly |
Non-immunogenic prodrugs and selectable markers for use in gene therapy
|
GB9708526D0
(en)
|
1997-04-25 |
1997-06-18 |
Royal Free Hosp School Med |
Eukaryotic gene expression cassette and uses thereof
|
US6210666B1
(en)
|
1997-10-21 |
2001-04-03 |
Orphan Medical, Inc. |
Truncated α-galactosidase A to treat fabry disease
|
EP1658857A1
(en)
|
1997-10-29 |
2006-05-24 |
Genzyme Corporation |
Compositions and methods for treating lysosomal storage disease
|
AU734290B2
(en)
|
1997-10-29 |
2001-06-07 |
Genzyme Corporation |
Compositions and methods for treating lysosomal storage disease
|
US6607879B1
(en)
|
1998-02-09 |
2003-08-19 |
Incyte Corporation |
Compositions for the detection of blood cell and immunological response gene expression
|
JP2002505085A
(ja)
|
1998-02-17 |
2002-02-19 |
ジェンザイム・コーポレイション |
精製aavベクターの生産方法
|
WO1999057296A1
(en)
|
1998-05-01 |
1999-11-11 |
Genzyme Corporation |
Partially deleted adenoviral vectors
|
US6274597B1
(en)
|
1998-06-01 |
2001-08-14 |
Mount Sinai School Of Medicine Of New York University |
Method of enhancing lysosomal α-Galactosidase A
|
US20020065236A1
(en)
|
1998-09-09 |
2002-05-30 |
Yew Nelson S. |
CpG reduced plasmids and viral vectors
|
US20090148906A1
(en)
|
1998-09-29 |
2009-06-11 |
Shire Human Genetic Therapies, Inc. A Delaware Corporation |
Optimized messenger rna
|
AU2004242550B2
(en)
|
1999-03-11 |
2008-04-03 |
Shire Human Genetic Therapies, Inc. |
Treatment of alpha-Galactosidase A deficiency
|
GB9909066D0
(en)
|
1999-04-20 |
1999-06-16 |
Oxford Glycosciences Uk Ltd |
Therapies
|
US7927587B2
(en)
|
1999-08-05 |
2011-04-19 |
Regents Of The University Of Minnesota |
MAPC administration for the treatment of lysosomal storage disorders
|
EP1325138B1
(en)
|
2000-10-11 |
2013-07-17 |
Shire Human Genetic Therapies, Inc. |
Optimized messenger rna
|
EP2275559A3
(en)
|
1999-09-28 |
2011-03-23 |
Shire Human Genetic Therapies, Inc. |
Optimized messenger RNA
|
WO2002064799A2
(en)
|
1999-09-28 |
2002-08-22 |
Transkaryotic Therapies, Inc. |
Optimized messenger rna
|
EP1242602B1
(en)
|
1999-11-05 |
2008-02-13 |
Jena Bioscience GmbH |
Protein expression systems in non-pathogenic kinetoplastidae
|
AU1920201A
(en)
|
1999-11-16 |
2001-05-30 |
Genzyme Corporation |
Improved regulatory elements for delivery to the liver
|
IL150314A0
(en)
|
1999-12-30 |
2002-12-01 |
Maxygen Aps |
Improved lysosomal enzymes and lysosomal enzyme activators
|
EP1261379A2
(en)
|
2000-02-17 |
2002-12-04 |
Genzyme Corporation |
Genetic modification of the lung as a portal for gene delivery
|
AU2001236713A1
(en)
|
2000-02-17 |
2001-08-27 |
Genzyme Corporation |
Methods for treatment of lysosomal storage diseases
|
US20020081654A1
(en)
|
2000-04-07 |
2002-06-27 |
Sandrin Mauro Sergio |
Targeting hydrolase enzymes
|
US20040204379A1
(en)
|
2000-06-19 |
2004-10-14 |
Cheng Seng H. |
Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
|
US20020095135A1
(en)
|
2000-06-19 |
2002-07-18 |
David Meeker |
Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
|
US20020014242A1
(en)
|
2000-07-31 |
2002-02-07 |
Abraham Scaria |
Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products
|
EP1624067A3
(en)
|
2000-09-18 |
2006-03-15 |
Genzyme Corporation |
Expression vectors containing hybrid ubiquitin promoters
|
AU2001290984A1
(en)
|
2000-09-18 |
2002-04-02 |
Genzyme Corporation |
Expression vectors containing hybrid ubiquitin promoters
|
US7723296B2
(en)
|
2001-01-18 |
2010-05-25 |
Genzyme Corporation |
Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
|
CA2448120A1
(en)
|
2001-05-24 |
2002-11-28 |
Genzyme Corporation |
Muscle-specific expression vectors
|
JP4742191B2
(ja)
|
2001-06-14 |
2011-08-10 |
独立行政法人産業技術総合研究所 |
糖蛋白質およびその製造方法
|
US7063962B2
(en)
|
2001-07-20 |
2006-06-20 |
Novozymes A/S |
DNA sequences for regulating transcription
|
US6749851B2
(en)
|
2001-08-31 |
2004-06-15 |
Clearant, Inc. |
Methods for sterilizing preparations of digestive enzymes
|
US6783968B2
(en)
|
2001-09-24 |
2004-08-31 |
Clearant, Inc. |
Methods for sterilizing preparations of glycosidases
|
US20030064000A1
(en)
|
2001-09-24 |
2003-04-03 |
Wilson Burgess |
Methods of sterilizing biological mixtures using stabilizer mixtures
|
US6723551B2
(en)
|
2001-11-09 |
2004-04-20 |
The United States Of America As Represented By The Department Of Health And Human Services |
Production of adeno-associated virus in insect cells
|
EP1336411A1
(en)
|
2002-02-14 |
2003-08-20 |
Academisch Medisch Centrum bij de Universiteit van Amsterdam |
Compositions and methods for improving enzyme replacement therapy of lysosomal storage diseases
|
EP2388265A1
(en)
|
2002-02-22 |
2011-11-23 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
JP5570677B2
(ja)
|
2002-04-25 |
2014-08-13 |
シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド |
α−ガラクトシダーゼA欠損症の治療
|
US20030225260A1
(en)
|
2002-04-30 |
2003-12-04 |
Snyder Richard O. |
Production of recombinant AAV virions
|
EP1521523A4
(en)
|
2002-05-20 |
2006-04-19 |
Univ Texas |
METHODS AND COMPOSITIONS FOR DELIVERING NUCLEIC ACID ENZYMES AND MOLECULES IN BRAIN, BONE, AND OTHER FABRICS
|
US20030224477A1
(en)
|
2002-05-31 |
2003-12-04 |
Heartlein Michael W. |
Optimized promoter constructs
|
AU2003273574A1
(en)
|
2002-05-31 |
2003-12-19 |
Osiris Therapeutics, Inc. |
Intraperitoneal delivery of genetically engineered mesenchymal stem cells
|
AU2003284357A1
(en)
|
2002-11-01 |
2004-06-07 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
WO2004047728A2
(en)
|
2002-11-26 |
2004-06-10 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
PT1587923E
(pt)
|
2003-01-22 |
2011-12-07 |
Univ Duke |
Construções melhoradas para a expressão de polipéptidos lisossomais
|
MX344587B
(es)
|
2003-01-31 |
2016-12-20 |
Mount Sinai School Of Medicine Of New York Univ |
Metodo para incrementar la estabilidad in vitro e in vivo de enzimas asociadas al transtorno lisosomal.
|
US7446098B2
(en)
|
2003-02-18 |
2008-11-04 |
Mount Sinai School Of Medicine Of New York University |
Combination therapy for treating protein deficiencies
|
JP2006520604A
(ja)
|
2003-03-19 |
2006-09-14 |
アイソジェニス・インコーポレイテッド |
CD8α鎖に基づき免疫原性が減少した遺伝子治療ベクター
|
US7951557B2
(en)
|
2003-04-27 |
2011-05-31 |
Protalix Ltd. |
Human lysosomal proteins from plant cell culture
|
US20100196345A1
(en)
|
2003-04-27 |
2010-08-05 |
Protalix |
Production of high mannose proteins in plant culture
|
JP4979067B2
(ja)
|
2003-05-01 |
2012-07-18 |
ジェンザイム・コーポレーション |
神経代謝性疾患についての遺伝子治療
|
JP2006525371A
(ja)
|
2003-05-05 |
2006-11-09 |
ジェンザイム コーポレイション |
免疫応答を減少させる方法
|
JP4917886B2
(ja)
|
2003-06-24 |
2012-04-18 |
ジェンザイム・コーポレーション |
新規β−アクチンおよびRPS21プロモーター、ならびにこれらの使用方法
|
WO2005019258A2
(en)
|
2003-08-11 |
2005-03-03 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
AU2004296848A1
(en)
|
2003-12-04 |
2005-06-23 |
Regents Of The University Of Minnesota |
Compositions and methods for the treatment of lysosomal storage disorders
|
WO2005074888A2
(en)
|
2004-02-03 |
2005-08-18 |
Biodelivery Sciences International, Inc. |
Replacement enzyme cochleates
|
EP1720405A4
(en)
|
2004-02-06 |
2008-08-27 |
Biomarin Pharm Inc |
MANUFACTURE OF HIGHLY PHOSPHORYLATED LYSOSOMAL ENZYMES AND USES THEREOF
|
US20050208090A1
(en)
|
2004-03-18 |
2005-09-22 |
Medtronic, Inc. |
Methods and systems for treatment of neurological diseases of the central nervous system
|
WO2006007560A2
(en)
|
2004-07-01 |
2006-01-19 |
University Of Pennsylvania |
Targeted protein replacement for the treatment of lysosomal storage disorders
|
US7892809B2
(en)
|
2004-12-15 |
2011-02-22 |
The University Of North Carolina At Chapel Hill |
Chimeric vectors
|
CA2607173C
(en)
|
2005-05-02 |
2018-04-24 |
Genzyme Corporation |
Composition comprising an adeno-associated virus vector having a serotype 1 capsid for use in treating lysosomal storage diseases or alzheimer's disease
|
US8500720B2
(en)
|
2005-05-09 |
2013-08-06 |
Medtronic, Inc |
Method and apparatus for treatment of cardiac disorders
|
US20110070201A1
(en)
|
2005-07-18 |
2011-03-24 |
Protalix Ltd. |
Mucosal or enteral administration of biologically active macromolecules
|
ES2661929T3
(es)
|
2005-10-31 |
2018-04-04 |
Velico Medical, Inc. |
Nuevas alfa-galactosidasas
|
WO2007058381A1
(ja)
|
2005-11-18 |
2007-05-24 |
Tokyo Metropolitan Organization For Medical Research |
基質特異性を変換した新規高機能酵素
|
AR059089A1
(es)
|
2006-01-20 |
2008-03-12 |
Genzyme Corp |
Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
|
US7867484B2
(en)
|
2006-01-27 |
2011-01-11 |
University Of North Carolina At Chapel Hill |
Heparin and heparan sulfate binding chimeric vectors
|
JP5706602B2
(ja)
|
2006-02-08 |
2015-04-22 |
ジェンザイム・コーポレーション |
ニーマンピック病a型に対する遺伝子治療
|
LT1988823T
(lt)
|
2006-02-09 |
2018-12-10 |
Genzyme Corporation |
Lėtas intraventrikuliarinis pateikimas
|
PL2533050T6
(pl)
|
2006-05-16 |
2016-05-31 |
Amicus Therapeutics Inc |
Możliwości leczenia choroby Fabry'ego
|
EP2121005A1
(en)
|
2006-12-21 |
2009-11-25 |
Academisch Ziekenhuis bij de Universiteit van Amsterdam |
Treatment of fabry disease
|
IL243117B2
(en)
|
2007-01-18 |
2023-03-01 |
Genzyme Corp |
Oligosaccharides containing an amino group and their conjugates
|
CA2584494A1
(en)
|
2007-03-27 |
2008-09-27 |
Jeffrey A. Medin |
Vector encoding therapeutic polypeptide and safety elements to clear transduced cells
|
AU2008232614A1
(en)
|
2007-03-30 |
2008-10-09 |
Amicus Therapeutics, Inc. |
Method for the treatment of Fabry disease using pharmacological chaperones
|
EP2150254A4
(en)
|
2007-04-26 |
2010-11-10 |
Amicus Therapeutics Inc |
DOSAGES FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES WITH PHARMACOLOGICAL CHAPTERONES
|
US9999618B2
(en)
|
2007-04-26 |
2018-06-19 |
Amicus Therapeutics, Inc. |
Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
|
WO2008154198A1
(en)
|
2007-06-06 |
2008-12-18 |
Genzyme Corporation |
Gene therapy for lysosomal storage diseases
|
EP2185187A1
(en)
|
2007-08-29 |
2010-05-19 |
Shire Human Genetic Therapies, Inc. |
Subcutaneous administration of alpha-galatosidase a
|
WO2009030254A1
(en)
|
2007-09-04 |
2009-03-12 |
Curevac Gmbh |
Complexes of rna and cationic peptides for transfection and for immunostimulation
|
US20100317690A1
(en)
|
2007-11-21 |
2010-12-16 |
Summit Corporation Plc |
Treatment of protein folding disorders
|
EP2242840B1
(en)
|
2008-01-29 |
2019-07-24 |
Applied Genetic Technologies Corporation |
Recombinant adeno-associated virus production using bhk cells in suspension
|
EP2252313B1
(en)
|
2008-02-12 |
2015-04-08 |
Amicus Therapeutics, Inc. |
Method to predict response to pharmacological chaperone treatment of diseases
|
US8568709B2
(en)
|
2008-03-20 |
2013-10-29 |
University Health Network |
Thymidylate kinase fusions and uses thereof
|
US8632764B2
(en)
|
2008-04-30 |
2014-01-21 |
University Of North Carolina At Chapel Hill |
Directed evolution and in vivo panning of virus vectors
|
PT2659904E
(pt)
|
2008-06-26 |
2016-01-22 |
Orphazyme Aps |
Uso da hsp70 como um regulador da atividade enzimática
|
WO2010015816A2
(en)
|
2008-08-06 |
2010-02-11 |
Summit Corporation Plc |
Treatment of lysosomal storage disorders and other proteostatic diseases
|
CN105879047A
(zh)
|
2008-12-16 |
2016-08-24 |
建新公司 |
寡糖-蛋白缀合物
|
US8889641B2
(en)
|
2009-02-11 |
2014-11-18 |
The University Of North Carolina At Chapel Hill |
Modified virus vectors and methods of making and using the same
|
GB0911870D0
(en)
|
2009-07-08 |
2009-08-19 |
Ucl Business Plc |
Optimised coding sequence and promoter
|
WO2011019980A1
(en)
|
2009-08-14 |
2011-02-17 |
University Of Miami |
Novel role of alpha-galactosidase activity as a biomarker in kidney disease
|
CN102712914A
(zh)
|
2009-09-29 |
2012-10-03 |
根特大学 |
水解甘露糖-1-磷酸-6-甘露糖连接为磷酸-6-甘露糖
|
WO2011041897A1
(en)
|
2009-10-06 |
2011-04-14 |
Angiochem Inc. |
Compositions and methods for the transport of therapeutic agents
|
PL2493487T3
(pl)
|
2009-10-27 |
2017-02-28 |
Erytech Pharma |
Kompozycja do indukowania swoistej tolerancji immunologicznej
|
US9724400B2
(en)
|
2009-11-09 |
2017-08-08 |
The Trustees Of The University Of Pennsylvania |
Administration of plant expressed oral tolerance agents
|
US20120230974A1
(en)
|
2009-11-17 |
2012-09-13 |
Protalix Ltd |
Alkaline alpha galactosidase for the treatment of fabry disease
|
US9194011B2
(en)
|
2009-11-17 |
2015-11-24 |
Protalix Ltd. |
Stabilized alpha-galactosidase and uses thereof
|
CA2781676C
(en)
|
2009-11-27 |
2020-05-05 |
Genzyme Corporation |
An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
|
US9169494B2
(en)
|
2010-01-12 |
2015-10-27 |
The University Of North Carolina At Chapel Hill |
Restrictive inverted terminal repeats for viral vectors
|
EP3088514B1
(en)
|
2010-03-02 |
2018-11-28 |
Protalix Ltd. |
Stabilized alpha-galactosidase and uses thereof
|
WO2011119773A1
(en)
|
2010-03-23 |
2011-09-29 |
Roeth Jeremiah F |
Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
|
US8809282B2
(en)
|
2010-05-06 |
2014-08-19 |
Duke University |
Method of reducing titers of antibodies specific for a therapeutic agent
|
DK2588130T3
(en)
|
2010-06-25 |
2016-10-24 |
Shire Human Genetic Therapies |
Cns delivery of therapeutic agents
|
US20130224757A1
(en)
|
2010-08-19 |
2013-08-29 |
Novozymes A/S |
Induced sporulation screening method
|
WO2012042386A2
(en)
|
2010-09-29 |
2012-04-05 |
Oxyrane Uk Limited |
Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated n-glycans and methods of facilitating mammalian cellular uptake of glycoproteins
|
WO2012075040A2
(en)
|
2010-11-30 |
2012-06-07 |
Shire Human Genetic Therapies, Inc. |
mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
|
KR101883803B1
(ko)
|
2011-01-20 |
2018-07-31 |
프로탈릭스 리미티드 |
식물 및 식물 세포에서 알파-갈락토시다제의 발현용 핵산 작제물
|
EP2683382B1
(en)
|
2011-03-11 |
2020-04-22 |
Amicus Therapeutics, Inc. |
Dosing regimens for the treatment of fabry disease
|
WO2012135857A1
(en)
|
2011-03-31 |
2012-10-04 |
University Of Iowa Research Foundation |
Methods and compositions for treating brain diseases
|
US20120283290A1
(en)
|
2011-05-06 |
2012-11-08 |
Amicus Therapeutics Inc. |
Quantitation of gl3 in urine
|
EP4043025A1
(en)
|
2011-06-08 |
2022-08-17 |
Translate Bio, Inc. |
Lipid nanoparticle compositions and methods for mrna delivery
|
AU2012359165A1
(en)
|
2011-12-22 |
2014-07-10 |
Centogene Ip Gmbh |
Combination of a compound having the ability to rearrange a lysosomal enzyme and ambroxol and/or a derivative of ambroxol
|
CN110917362A
(zh)
|
2012-02-07 |
2020-03-27 |
全球生物疗法有限公司 |
核酸输送的区室化方法及其组合物和应用
|
WO2013120497A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
|
ES2868174T3
(es)
|
2012-03-29 |
2021-10-21 |
Translate Bio Ma Inc |
Lípidos catiónicos ionizables
|
CA2868391A1
(en)
|
2012-04-02 |
2013-10-10 |
Stephane Bancel |
Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
EP2833923A4
(en)
|
2012-04-02 |
2016-02-24 |
Moderna Therapeutics Inc |
MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS
|
DK2839001T3
(en)
|
2012-04-18 |
2017-12-11 |
Vib Vzw |
METHODS AND PROCEDURES FOR THE PREPARATION OF IMPROVED PROTEINS
|
EP2846821B1
(en)
|
2012-05-03 |
2020-03-11 |
Indiana University Research&Technology Corporation |
Hydrodynamic methods for delivering fluids to kidney tissues and related materials and methods
|
WO2013181454A1
(en)
|
2012-05-30 |
2013-12-05 |
Biostrategies LC |
Plant lectins as carriers of associated drug substances into animal and human cells
|
US10648001B2
(en)
|
2012-07-11 |
2020-05-12 |
Sangamo Therapeutics, Inc. |
Method of treating mucopolysaccharidosis type I or II
|
HUE030799T2
(en)
|
2012-07-11 |
2017-06-28 |
Sangamo Biosciences Inc |
Methods and preparations for the treatment of lysosomal storage diseases
|
CA2917995C
(en)
|
2012-07-17 |
2021-01-26 |
Amicus Therapeutics, Inc. |
Alpha-galactosidase a and 1-deoxygalactonojirimycin co-formulation
|
GB201213117D0
(en)
|
2012-07-24 |
2012-09-05 |
Ucl Business Plc |
Transgene expression
|
WO2014017915A2
(en)
|
2012-07-27 |
2014-01-30 |
Universiteit Utrecht Holding B.V. |
Urea and guanidinium derivatives of iminosugars
|
AU2013296557B2
(en)
|
2012-07-31 |
2019-04-18 |
Bioasis Technologies Inc. |
Dephosphorylated lysosomal storage disease proteins and methods of use thereof
|
US10138474B2
(en)
|
2012-08-17 |
2018-11-27 |
Research Foundation Of The City University Of New York |
Scavenger receptor uptake for fabry disease enzyme replacement therapy
|
EP2929035A1
(en)
|
2012-12-07 |
2015-10-14 |
Shire Human Genetic Therapies, Inc. |
Lipidic nanoparticles for mrna delivering
|
WO2014120900A1
(en)
|
2013-01-31 |
2014-08-07 |
Icahn School Of Medicine At Mount Sinai |
Enhanced therapeutic regimens for treating fabry disease
|
EP2970946A4
(en)
|
2013-03-13 |
2016-09-07 |
Philadelphia Children Hospital |
ADENOASSOZED VIRUS VECTORS AND METHOD FOR USE THEREOF
|
SG11201507474QA
(en)
|
2013-03-14 |
2015-10-29 |
Shire Human Genetic Therapies |
RIBONUCLEIC ACIDs WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS
|
EP2976092B1
(en)
|
2013-03-15 |
2020-04-22 |
Amicus Therapeutics, Inc. |
Chemical crosslinkers
|
EP2970966A4
(en)
|
2013-03-15 |
2016-10-26 |
Univ North Carolina |
SYNTHETIC ADENOASSOZED VIRUS INVERTED REPEAT SEQUENCES
|
WO2015012924A2
(en)
|
2013-04-29 |
2015-01-29 |
The Trustees Of The University Of Pennsylvania |
Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof
|
SG10201710448SA
(en)
|
2013-05-15 |
2018-01-30 |
Univ Minnesota |
Adeno-associated virus mediated gene transfer to the central nervous system
|
EP3008191A2
(en)
|
2013-06-13 |
2016-04-20 |
Shire Human Genetic Therapies, Inc. |
Messenger rna based viral production
|
US20140377246A1
(en)
|
2013-06-19 |
2014-12-25 |
Carol Ann Foundation and International Morquio Organization |
Enzyme replacement therapy for treating mps vii related bone lesions using a chemically modified enzyme
|
BR112016001592A2
(pt)
|
2013-07-26 |
2017-11-28 |
Univ Iowa Res Found |
métodos e composições para o tratamento de doenças cerebrais
|
EP3033102B2
(en)
|
2013-08-13 |
2023-12-20 |
Northwestern University |
Peptide conjugated particles
|
TWI793159B
(zh)
|
2013-10-23 |
2023-02-21 |
美商健臻公司 |
重組醣蛋白及其用途
|
US20160243260A1
(en)
|
2013-10-24 |
2016-08-25 |
Uniqure Ip B.V. |
Treatment of neurological diseases using adeno-associated virus (AAV) comprising AAV-5 capsid proteins
|
SI3068869T1
(sl)
|
2013-11-15 |
2020-11-30 |
The Trustees Of The University Of Pennsylvania |
Sestavki za supresijo tvorbe inhibitorja proti faktorju VIII pri pacientih s hemofilijo A
|
PL3079695T3
(pl)
|
2013-12-11 |
2021-09-27 |
Genzyme Corporation |
Inhibitory syntazy glukozyloceramidu
|
RU2685269C2
(ru)
|
2013-12-23 |
2019-04-17 |
БКН Пептидес, С.А. |
Аналоги бикалутамида или (s)-бикалутамид в качестве активирующих экзоцитоз соединений для применения в лечении расстройства лизосомного накопления или гликогеноза
|
WO2015119989A1
(en)
|
2014-02-04 |
2015-08-13 |
New York University |
Progranulin (pgrn) and its derivatives for diagnosis and treatment of lysosomal storage diseases
|
ES2879636T3
(es)
|
2014-05-02 |
2021-11-22 |
Genzyme Corp |
Vectores AAV para la terapia génica de la retina y el SNC
|
JP6652334B2
(ja)
|
2014-05-31 |
2020-02-19 |
Jcrファーマ株式会社 |
ウリジンとn−アセチル−d−マンノサミンとを含有する培地
|
WO2016037163A1
(en)
|
2014-09-07 |
2016-03-10 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses
|
EP3218000A2
(en)
|
2014-11-10 |
2017-09-20 |
Alexion Pharmaceuticals, Inc. |
Therapeutic compositions of alpha-l-iduronidase, iduronate-2-sulfatase, and alpha-galactosidase a and methods of use thereof
|
TW201632626A
(zh)
|
2014-11-21 |
2016-09-16 |
臺北榮民總醫院 |
製備誘導性多功能幹細胞之方法
|
PT4023755T
(pt)
|
2014-12-12 |
2023-07-05 |
CureVac SE |
Moléculas de ácido nucleico artificiais para uma expressão melhorada de proteína
|
US10889834B2
(en)
|
2014-12-15 |
2021-01-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing targeted transgene integration
|
DK3237621T3
(da)
|
2014-12-22 |
2023-06-19 |
Codexis Inc |
Varianter af human alpha-galactosidase
|
CN107124889A
(zh)
|
2014-12-30 |
2017-09-01 |
库瑞瓦格股份公司 |
人工核酸分子
|
WO2016115382A1
(en)
|
2015-01-14 |
2016-07-21 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for targeted gene transfer
|
US10350245B2
(en)
|
2015-01-21 |
2019-07-16 |
Fred Hutchinson Cancer Research Center |
Point-of-care and/or portable platform for gene therapy
|
EP4219728A3
(en)
|
2015-02-10 |
2023-08-23 |
Genzyme Corporation |
Enhanced delivery of viral particles to the striatum and cortex
|
KR20170116159A
(ko)
|
2015-02-19 |
2017-10-18 |
다니스코 유에스 인크. |
향상된 단백질 발현
|
US20180135074A1
(en)
|
2015-02-19 |
2018-05-17 |
University Of Florida Research Foundation, Incorporated |
Recombinant aav vectors for gene therapy of human hematopoietic disorders
|
ES2899783T3
(es)
|
2015-03-17 |
2022-03-14 |
eleva GmbH |
Proteínas lisosómicas glucosiladas, método de producción y utilizaciones
|
WO2016154313A1
(en)
|
2015-03-24 |
2016-09-29 |
Zywie, Llc |
High drug loading liquid oral pharmaceutical compositions
|
WO2016154344A1
(en)
|
2015-03-24 |
2016-09-29 |
The Regents Of The University Of California |
Adeno-associated virus variants and methods of use thereof
|
US9981021B1
(en)
|
2015-04-09 |
2018-05-29 |
Kinetiq, Inc. |
Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof
|
CA3019315A1
(en)
|
2015-04-23 |
2016-10-27 |
University Of Massachusetts |
Modulation of aav vector transgene expression
|
GB201508025D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Fabry disease gene therapy
|
CN108367055A
(zh)
|
2015-05-15 |
2018-08-03 |
明尼苏达大学董事会 |
用于治疗性递送到中枢神经***的腺相关物
|
EP3303377B1
(en)
|
2015-06-05 |
2022-11-23 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for transient gene therapy with enhanced stability
|
MX2017017062A
(es)
|
2015-07-01 |
2018-09-05 |
The Regents Of Univ Of California |
Vectores retrovirales que contienen un promotor de ubiquitina c humana de orientacion inversa.
|
US11390656B2
(en)
|
2015-08-04 |
2022-07-19 |
New York University |
Progranulin (PGRN) fragments and derivatives for treatment or alleviation of lysosomal storage diseases
|
US20170051267A1
(en)
|
2015-08-20 |
2017-02-23 |
Research Foundation Of The City University Of New York |
Novel alpha-galactosidase a derivatives
|
WO2017049161A1
(en)
|
2015-09-18 |
2017-03-23 |
Duke University |
ACID ALPHA-GLUCOSIDASE AND A β-2 AGONIST FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDER
|
SG11201804375WA
(en)
|
2015-12-08 |
2018-06-28 |
Regeneron Pharma |
Compositions and methods for internalizing enzymes
|
AU2016371779C1
(en)
|
2015-12-14 |
2022-10-13 |
The University Of North Carolina At Chapel Hill |
Modified capsid proteins for enhanced delivery of parvovirus vectors
|
GB201522243D0
(en)
|
2015-12-16 |
2016-01-27 |
Ucl Business Plc |
Treatment
|
EP3380496B1
(en)
|
2015-12-23 |
2020-05-20 |
Danisco US Inc. |
Enhanced protein production and methods thereof
|
CA3009799A1
(en)
|
2016-01-04 |
2017-07-13 |
Cour Pharmaceuticals Development Company Inc. |
Particles encapsulating fusion proteins containing linked epitopes
|
EP3402531A4
(en)
|
2016-01-11 |
2019-08-14 |
Medgenics Medical Israel Ltd |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
|
AR107483A1
(es)
|
2016-01-29 |
2018-05-02 |
Hanmi Pharm Ind Co Ltd |
Conjugado de enzimas terapéuticas
|
WO2017136202A1
(en)
|
2016-02-05 |
2017-08-10 |
Emory University |
Injection of single-stranded or self-complementary adeno-associated virus 9 into the cerebrospinal fluid
|
US11078247B2
(en)
|
2016-05-04 |
2021-08-03 |
Curevac Ag |
RNA encoding a therapeutic protein
|
US20180126003A1
(en)
|
2016-05-04 |
2018-05-10 |
Curevac Ag |
New targets for rna therapeutics
|